Related Experiment Video
Updated: May 2, 2026

08:23
Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
Published on: November 29, 2019
11.1K
[Quantitative analysis of cerebrospinal fluid flow in multiple sclerosis patients]
D V Nikitin1, A N Boyko1, O V Boyko1,2
1Federal Center for Brain and Neurotechnologies, Moscow, Russia.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|August 8, 2025
Summary
Multiple sclerosis (MS) significantly disrupts cerebrospinal fluid (CSF) flow, especially during acute stages. Phase contrast MRI reveals these changes, aiding in monitoring disease activity and treatment effectiveness.
Area of Science:
- Neuroimaging
- Neurology
- Fluid dynamics
Context:
- Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system.
- Cerebrospinal fluid (CSF) dynamics play a crucial role in brain health and function.
- Quantitative assessment of CSF flow is essential for understanding disease mechanisms.
Purpose:
- To investigate alterations in quantitative indicators of intracranial CSF flow in MS patients across different disease stages.
- To utilize phase contrast magnetic resonance imaging (PC MRI) for precise measurement of CSF flow parameters.
- To compare CSF flow dynamics between acute MS, remitting MS, and healthy controls.
Summary:
- Phase contrast MRI revealed significantly reduced CSF flow velocities and volumes in the acute stage of MS compared to remission and healthy controls.
- Patients in remission showed partial recovery of CSF flow, but parameters remained below those of healthy volunteers.
- Specific quantitative reductions observed include peak positive flow rate (35% lower), peak negative flow rate (36% lower), positive volume (49% lower), and negative volume (37% lower) in the acute stage.
Impact:
- Disordered CSF flow in acute MS may serve as a potential biomarker for inflammation activity.
- PC MRI offers a valuable tool for monitoring CSF circulation in MS patients.
- This technique can aid in evaluating the efficacy of therapeutic interventions for MS.

